Efficacy and tolerability of the dietary supplement “Altsinara” in subjects with hypercholesterolemia: a laboratory component of the clinical study

Abstract

The importance of dyslipidemia as one of the main risk factors of cardiovascular disease is currently undoubted. Medicines of plant origin with the anti-atherogenic potential are of particular relevance for prevention of the dyslipidemia development of borderline states.Aim. To study the laboratory component of the efficacy and tolerability of the dietary supplement “Altsinara”, produced by PJSC SIC “Borshchahivskiy CPP” compared to placebo in subjects with hypercholesterolemia in the framework of the clinical study “Randomized, simple blind, placebo-controlled study of the efficacy and tolerability of dietary supplement “Altsinara” produced by PJSC SIC “Borshchahivskiy CPP” with the participation of volunteers with hypercholesterolemia”.Materials and methods. The study was conducted with the participation of 60 volunteers with hypercholesterolemia, whose average age was 48.83 ± 1.17 years. To assess the laboratory component of the effectiveness and tolerability of the dietary supplement “Altsinara” the indicators of the clinical and biochemical blood test were used for 1 (screening), 3 (day 45) and 4 (final day 90) visit.Results. The prevailing efficacy and good tolerability of long-term use (within 90 days) of a dietary supplement “Altsinara”, tablets produced by PJSC SIC “Borshchahivskiy CPP”, Ukraine, have been proven. Based on the results of the test a dietary supplement “Altsinara”, tablets produced by PJSC SIC “Borshchahivskiy CPP”, Ukraine, can be recommended as a special food product for long-term use in persons with hypercholesterolemia and/or persons with a tendency to hypercholesterolemia (aggravated family history, overweight, inappropriate nutrition, etc.).Conclusions. Based on the results of a randomized, simple blind, placebo-controlled study on the effectiveness and tolerability of the dietary supplement “Altsinara” produced by PJSC SIC “Borshchahivskiy CPP” with the participation of volunteers with hypercholesterolemia its prevailing efficacy and good tolerability in long-term use (within 90 days) have been proven.